$MRK
Merck & Co., Inc.
Global pharmaceutical leader known for Keytruda cancer immunotherapy and vaccines.
MRK key facts as of November 14, 2026
- Latest AI research report
- MRK Stock Analysis: Pipeline and Valuation (as of November 14, 2026)
- StockAlpha report sentiment
- Neutral (as of November 14, 2026)
- Analyst consensus
- Strong Buy (5 Strong Buy, 14 Buy, 9 Hold, 0 Sell, 0 Strong Sell) (as of November 1, 2026)
- Analyst price target
- $159.45 mean (range $105.00 to $180.00) (as of November 17, 2026)
- Sector
- Healthcare
Analysis from Nov 13, 2026
MRK Stock Analysis: Pipeline and Valuation
Merck closed Friday, November 13, at $147.76 after a recent quarterly earnings beat and two positive EU committee opinions. Pipeline progress and a 2.3% dividend yield are balanced by negative earnings growth, meaningful debt and uncertainty around future growth as Keytruda approaches patent-related challenges.
Previous Reports
MRK FAQ
What is StockAlpha's latest view on MRK?
StockAlpha's latest AI research report on Merck & Co., Inc. (MRK), "MRK Stock Analysis: Pipeline and Valuation", was published on November 14, 2026 and rates the overall sentiment as neutral. Merck closed Friday, November 13, at $147.76 after a recent quarterly earnings beat and two positive EU committee opinions. Pipeline progress and a 2.3% dividend yield are balanced by negative earnings growth, meaningful debt and uncertainty around future growth as Keytruda approaches patent-related challenges.
When was the MRK research last updated?
The most recent MRK report was published on November 14, 2026.
What do analysts expect for MRK?
As of November 1, 2026, the analyst consensus on MRK is Strong Buy (5 Strong Buy, 14 Buy, 9 Hold, 0 Sell, 0 Strong Sell). As of November 17, 2026, the analyst price target is $159.45 mean (range $105.00 to $180.00).
Is this MRK research investment advice?
No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.
Keep exploring
- draft Merck & Co. into a free practice contest: How to put the stock you just researched into a contest lineup at no real-money risk
- the healthcare sector brief for context on Merck & Co.'s peers: Today's sector-level news and moves around the stock